Our proprietary chemistry offers an entirely new and simple approach for detecting very small quantities of mutant DNA within a sample. The method allows us to significantly exceed the current limitations of detection without requiring DNA sequencing or complex bioinformatics, presenting exciting opportunities in the world of patient monitoring and screening, and precision treatment. We believe that we can move fast to commercialise our system and Heiner Dreismann’s market insights and knowledge of the industry will be invaluable as we begin validating the chemistry for a range of different applications.
Dr Barnaby Balmforth
Chief Executive Officer, Biofidelity
Veteran Roche executive with more than 35 years of industry experience
Pioneer in the early adoption of polymerase chain reaction (PCR) technology
Cambridge, UK, 15 July 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the members of its newly-formed Scientific Advisory...